BioLineRx Ltd. (BLRX) PT Set at $3.00 by Maxim Group
BioLineRx Ltd. (NASDAQ:BLRX) has been assigned a $3.00 target price by Maxim Group in a note issued to investors on Tuesday. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Maxim Group’s price objective points to a potential upside of 154.24% from the stock’s current price.
BLRX has been the topic of several other reports. Zacks Investment Research upgraded BioLineRx from a “hold” rating to a “buy” rating and set a $1.00 target price on the stock in a research note on Friday, April 21st. HC Wainwright set a $4.00 target price on BioLineRx and gave the stock a “buy” rating in a research note on Tuesday, April 18th. Oppenheimer Holdings, Inc. began coverage on BioLineRx in a research note on Friday. They set an “outperform” rating and a $3.00 target price on the stock. Roth Capital began coverage on BioLineRx in a research note on Thursday, August 3rd. They set a “buy” rating and a $3.00 target price on the stock. Finally, ValuEngine upgraded BioLineRx from a “sell” rating to a “hold” rating in a research note on Monday, July 17th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $2.59.
BioLineRx (BLRX) traded up 3.51% during midday trading on Tuesday, hitting $1.18. The company had a trading volume of 1,123,323 shares. BioLineRx has a 52 week low of $0.79 and a 52 week high of $1.42. The stock’s market capitalization is $72.90 million. The stock has a 50 day moving average price of $0.91 and a 200-day moving average price of $0.96.
BioLineRx (NASDAQ:BLRX) last released its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.05) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.05). On average, equities analysts predict that BioLineRx will post ($0.25) EPS for the current year.
A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Citadel Advisors LLC increased its stake in BioLineRx by 443.4% in the first quarter. Citadel Advisors LLC now owns 105,986 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 86,481 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in BioLineRx during the first quarter valued at about $126,000. Benchmark Capital Advisors increased its stake in BioLineRx by 227.3% in the first quarter. Benchmark Capital Advisors now owns 144,000 shares of the biotechnology company’s stock valued at $138,000 after buying an additional 100,000 shares during the last quarter. KCG Holdings Inc. increased its stake in BioLineRx by 715.9% in the first quarter. KCG Holdings Inc. now owns 175,156 shares of the biotechnology company’s stock valued at $168,000 after buying an additional 153,687 shares during the last quarter. Finally, Sabby Management LLC acquired a new stake in BioLineRx during the first quarter valued at about $3,018,000. Hedge funds and other institutional investors own 34.91% of the company’s stock.
BioLineRx Company Profile
BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.
Receive News & Stock Ratings for BioLineRx Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx Ltd. and related stocks with our FREE daily email newsletter.